227 related articles for article (PubMed ID: 16865244)
1. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
3. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
5. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
8. Chemo-radio-gene therapy for colorectal cancer cells using Escherichia coli uracil phosphoribosyltransferase gene.
Koyama F; Fujii H; Mukogawa T; Ueno M; Hamada H; Ishikawa H; Doi S; Nakao T; Matsumoto H; Shimatani H; Takeuchi T; Nakajima Y
Anticancer Res; 2003; 23(2B):1343-8. PubMed ID: 12820392
[TBL] [Abstract][Full Text] [Related]
9. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
[TBL] [Abstract][Full Text] [Related]
10. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
11. Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
Nakagawa T; Otsuki N; Masai Y; Sasaki R; Tsukuda M; Nibu K
Acta Otolaryngol; 2008 Aug; 128(8):936-40. PubMed ID: 18607998
[TBL] [Abstract][Full Text] [Related]
12. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
Ojima E; Inoue Y; Watanabe H; Hiro J; Toiyama Y; Miki C; Kusunoki M
Oncol Rep; 2006 Nov; 16(5):1085-91. PubMed ID: 17016597
[TBL] [Abstract][Full Text] [Related]
13. Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma.
Harada K; Ferdous T; Yoshida H
Oncol Rep; 2007 Nov; 18(5):1077-83. PubMed ID: 17914556
[TBL] [Abstract][Full Text] [Related]
14. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T
Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741
[TBL] [Abstract][Full Text] [Related]
16. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
17. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models.
Stackhouse MA; Pederson LC; Grizzle WE; Curiel DT; Gebert J; Haack K; Vickers SM; Mayo MS; Buchsbaum DJ
Gene Ther; 2000 Jun; 7(12):1019-26. PubMed ID: 10871750
[TBL] [Abstract][Full Text] [Related]
18. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Diagaradjane P; Guha S; Deorukhkar A; Shentu S; Aggarwal BB; Krishnan S
Clin Cancer Res; 2008 Apr; 14(7):2128-36. PubMed ID: 18381954
[TBL] [Abstract][Full Text] [Related]
19. Preclinical analysis of the antitumor efficacy of TS-1 using human uterine cervical cancer tumor xenografts.
Nagai N; Komatsu M; Yunokawa M; Shiroyama Y; Hirata E
Oncol Rep; 2008 Nov; 20(5):1149-56. PubMed ID: 18949415
[TBL] [Abstract][Full Text] [Related]
20. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
